Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kanitinib in Advanced Solid Tumors
NCT04093466Phase 1Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kanitinib in solid tumor, sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicities and Maximum Tolerated Dose. Started Apr 2020; status: recruiting.
02
Drugs
kanitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04093466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093466.